Article

Omega-3 supplement decreases dry eye symptoms in clinical trial

Patients taking an omega-3 supplement (TheraTears Nutrition, Advanced Vision Research) had a self-reported reduction in dry eye symptoms and an increase in tear volume and tear flow compared with a group of controls who received placebos, according to a pilot trial of dry eye patients reported in the journal Cornea.

Woburn, MA-Patients taking an omega-3 supplement had a self-reported reduction in dry eye symptoms and an increase in tear volume and tear flow compared with a group of controls who received placebos, according to a pilot trial of patients with dry eye reported in the journal Cornea.

A total of 36 patients with dry eye completed the prospective, randomized, double-masked study. Patients with dry eye received a daily supplement of fish oil-containing 450 mg of eicosapentaenoic acid, 300 mg of docosahexaenoic acid, and 1,000 mg of flaxseed oil (TheraTears Nutrition, Advanced Vision Research)-or placebo for 90 days. At two visits (baseline and final), patients scored their symptoms on the Ocular Surface Disease Index and underwent tests, including slit-lamp examinations, breakup time, corneal staining, Schirmer type I, fluorophotometry, evaporometry, and collection of meibomian gland secretion samples.

After 90 days, 70% of the patients with dry eye who received the supplement reported having no symptoms of dry eye, compared with 7% of the patients in the placebo group. Although no significant differences were found in meibum lipid composition or aqueous tear evaporation rate between the two groups, mean tear flow was 0.10 μl/min higher, and mean tear volume was 0.94 μl higher in the supplement group compared with the placebo group.

“This study demonstrates the potential of [the omega-3-based supplement] in reducing the debilitating effects of dry eye from both the patient and physician perspective,” said James P. McCulley, MD, professor and chairman of the department of ophthalmology at the University of Texas Southwestern Medical School, Dallas, and senior author of the study. “It is particularly interesting to see these clinical results, since we know that omega-3 [fatty acids] have been shown to reduce the effects of inflammation and influence the composition of the tear film, two factors that play an important role in dry eye.”

Although this study provides interesting insight into the effects of supplementation on dry eye disease, more research should be done to understand fully how omega-3 [fatty acids] work on a cellular level, Dr. McCulley added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.